InAdvance Team's Fundraising Page

InAdvanceTeam Front Row: Irene Ghobrial, Elizabeth Kitzenberg, Camille Gladieux, Sapna Syngal, David Read. Back row: Tim Rebbeck, Giovanni Parmigiani
InAdvanceTeam Front Row: Irene Ghobrial, Elizabeth Kitzenberg, Camille Gladieux, Sapna Syngal, David Read. Back row: Tim Rebbeck, Giovanni Parmigiani

WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER

What Is InAdvance?

InAdvance is a Dana-Farber strategic initiative designed to disrupt the historical cancer care model by bringing state-of-the-art early detection and precision intervention to people at higher risk of developing cancer.

InAdvance was launched in 2022 by Dana-Farber President and CEO Laurie Glimcher, MD, with a multi-disciplinary faculty leadership team and disease center champions across Dana-Farber’s early detection clinical programs. This integrated research-clinical model will accelerate understanding of precursor conditions that precede cancer and bring earlier interventions for patients more rapidly.

Through both research and clinical offerings, InAdvance serves people at elevated risk for developing cancer. This includes people with precursor conditions, environmental exposures, cancer survivors at elevated risk of developing secondary cancers, and those with a family history of cancer.

PROGRESS TO GOAL

Raised:$151
Goal:$10,000
2team members

THANK YOU TO OUR TEAM MEMBERS

C = Team Captain
NAME
AMOUNT RAISED
x2x
x$151.00x

THANK YOU TO OUR TEAM DONORS

NAME
AMOUNT
Team Honor Roll
Mrs. Elizabeth Kitzenberg
$71
Mx. Camille Gladieux
$80
I'm Living Proof buttons
Every dollar raised helps fuel Dana-Farber Cancer Institute's 50-50 balance between lifesaving research and total patient care.
Together, we can conquer cancer!














The 2022 Boston Marathon Jimmy Fund Walk

InAdvanceTeam Front Row: Irene Ghobrial, Elizabeth Kitzenberg, Camille Gladieux, Sapna Syngal, David Read. Back row: Tim Rebbeck, Giovanni Parmigiani
InAdvanceTeam Front Row: Irene Ghobrial, Elizabeth Kitzenberg, Camille Gladieux, Sapna Syngal, David Read. Back row: Tim Rebbeck, Giovanni Parmigiani

InAdvance Team

What Is InAdvance?

InAdvance is a Dana-Farber strategic initiative designed to disrupt the historical cancer care model by bringing state-of-the-art early detection and precision intervention to people at higher risk of developing cancer.

InAdvance was launched in 2022 by Dana-Farber President and CEO Laurie Glimcher, MD, with a multi-disciplinary faculty leadership team and disease center champions across Dana-Farber’s early detection clinical programs. This integrated research-clinical model will accelerate understanding of precursor conditions that precede cancer and bring earlier interventions for patients more rapidly.

Through both research and clinical offerings, InAdvance serves people at elevated risk for developing cancer. This includes people with precursor conditions, environmental exposures, cancer survivors at elevated risk of developing secondary cancers, and those with a family history of cancer.

View More
View More